
Allergy News
Read about all the latest research and advancements going on in the food allergy community.
Thursday, September 16th 2021
FDA approves IND application for peanut allergy drug candidate
by Outsourcing-pharma
The US agency has given the go-ahead to Cour Pharmaceuticals to evaluate the safety and efficacy of CNP-201, a drug intended to treat peanut allergies.
READ ARTICLE HIDE ARTICLE
By Jenni Spinner
Cour Pharmaceuticals, a biotechnology firm working on novel nanoparticles to treat immune disorders, has announced the US Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for its CNP-201. The proof-of-concept study will test the safety and efficacy of the drug in a proof-of-concept (Phase I/II) study in patients suffering from an allergy to peanuts.
Jon Puisis (president, CEO, and co-founder of Cour) said, "This will be the first clinical trial with a first-in-class therapy to reprogram the immune system to stop the allergic response to peanuts. Our hope is the clinical trials will confirm that CNP-201 can help eliminate the potentially fatal health risks associated with patients who have a peanut allergy."
CNP-201 is a biodegradable nanoparticle that encapsulates purified peanut protein extract and is administered via intravenous infusion. The nanoparticles containing peanut allergens are consumed by immune-presenting cells; when the particles and allergens are presented by the immune-presenting cell, they trigger reprogramming of the cellular functions of the immune system, reducing and possibly eliminating the potential risk of severe allergic reactions.
https://www.outsourcing-pharma.com/Article/2021/09/16/FDA-approves-IND-application-for-peanut-allergy-drug-candidate
Learn More from Outsourcing-pharma
Have an opinion on this news article?